QUEST DIAGNOSTICS INC — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Davis J. E. | CEO and President | Tax Withholding | 31,656 | $173.74 | $5,499,913 | 166,814 | Mar 4, 2025 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Tax Withholding | 992 | $173.74 | $172,350 | 10,564 | Mar 4, 2025 |
| Plewman Patrick | SVP for Diagnostic Services | Award / Grant | 5,674 | $173.74 | $985,801 | 23,430 | Mar 4, 2025 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Tax Withholding | 3,906 | $173.74 | $678,628 | 42,760 | Mar 4, 2025 |
| DELANEY MARK E | SVP & Chief Commercial Officer | Tax Withholding | 1,823 | $173.74 | $316,728 | 9,477 | Mar 4, 2025 |
| SAMAD SAM | Executive Vice President & CFO | Award / Grant | 13,884 | $173.74 | $2,412,206 | 34,061 | Mar 4, 2025 |
| Doherty Catherine T. | EVP, Regional Businesses | Tax Withholding | 455 | $171.75 | $78,146 | 70,002 | Feb 27, 2025 |
| SAMAD SAM | Executive Vice President & CFO | Tax Withholding | 869 | $171.75 | $149,251 | 20,177 | Feb 26, 2025 |
| Davis J. E. | CEO and President | Tax Withholding | 2,966 | $171.75 | $509,411 | 138,215 | Feb 26, 2025 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sale | 528 | $172.61 | $91,138 | 39,031 | Feb 26, 2025 |
| Plewman Patrick | SVP for Diagnostic Services | Tax Withholding | 229 | $171.75 | $39,331 | 17,853 | Feb 26, 2025 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Tax Withholding | 233 | $171.75 | $40,018 | 11,546 | Feb 26, 2025 |
| DEPPE MICHAEL J | SVP, Corp. Controller & CAO | Tax Withholding | 88 | $171.75 | $15,114 | 35,212 | Feb 26, 2025 |
| DELANEY MARK E | SVP & Chief Commercial Officer | Tax Withholding | 214 | $171.75 | $36,755 | 5,983 | Feb 26, 2025 |
| Doherty Catherine T. | EVP, Regional Businesses | Sale | 535 | $169.71 | $90,795 | 71,356 | Feb 20, 2025 |
| SAMAD SAM | Executive Vice President & CFO | Tax Withholding | 1,031 | $169.71 | $174,971 | 21,046 | Feb 19, 2025 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sale | 604 | $170.99 | $103,278 | 39,845 | Feb 19, 2025 |
| Plewman Patrick | SVP for Diagnostic Services | Sale | 320 | $169.71 | $54,307 | 18,082 | Feb 19, 2025 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Tax Withholding | 287 | $169.71 | $48,707 | 11,779 | Feb 19, 2025 |
| DEPPE MICHAEL J | SVP, Corp. Controller & CAO | Tax Withholding | 99 | $169.71 | $16,801 | 35,300 | Feb 19, 2025 |
| DELANEY MARK E | SVP & Chief Commercial Officer | Tax Withholding | 242 | $169.71 | $41,070 | 6,197 | Feb 19, 2025 |
| Davis J. E. | CEO and President | Tax Withholding | 2,936 | $169.71 | $498,269 | 141,181 | Feb 19, 2025 |
| Davis J. E. | CEO and President | Award / Grant | 18,149 | — | — | 144,117 | Feb 12, 2025 |
| SAMAD SAM | Executive Vice President & CFO | Award / Grant | 4,538 | — | — | 22,077 | Feb 12, 2025 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Award / Grant | 2,345 | — | — | 40,823 | Feb 12, 2025 |
| Plewman Patrick | SVP for Diagnostic Services | Award / Grant | 2,042 | — | — | 18,402 | Feb 12, 2025 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Award / Grant | 2,269 | — | — | 12,066 | Feb 12, 2025 |
| Doherty Catherine T. | EVP, Regional Businesses | Award / Grant | 3,479 | — | — | 71,891 | Feb 12, 2025 |
| DELANEY MARK E | SVP & Chief Commercial Officer | Award / Grant | 1,815 | — | — | 6,439 | Feb 12, 2025 |
| DEPPE MICHAEL J | SVP, Corp. Controller & CAO | Award / Grant | 454 | — | — | 35,399 | Feb 12, 2025 |
| Gregg Vicky B | — | Sale | 1,250 | $164.57 | $205,713 | 16,867 | Feb 5, 2025 |
| DELANEY MARK E | SVP & Chief Commercial Officer | Sale | 403 | $164.30 | $66,213 | 4,624 | Feb 5, 2025 |
| Gregg Vicky B | — | L | 72 | $158.04 | $11,379 | 18,117 | Jan 29, 2025 |
| SAMAD SAM | Executive Vice President & CFO | L | 35 | $158.04 | $5,531 | 17,539 | Jan 29, 2025 |
| Plewman Patrick | SVP for Diagnostic Services | L | 57 | $158.04 | $9,008 | 16,345 | Jan 29, 2025 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | 12 | $158.03 | $1,896 | 9,780 | Jan 29, 2025 |
| DELANEY MARK E | SVP & Chief Commercial Officer | L | 4 | $158.03 | $632 | 5,027 | Jan 29, 2025 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sale | 32,137 | $163.15 | $5,243,152 | 38,478 | Nov 29, 2024 |
| Doherty Catherine T. | EVP, Regional Businesses | Option Exercise | 33,103 | $103.57 | $3,428,478 | 101,515 | Nov 27, 2024 |
| DEPPE MICHAEL J | SVP, Corp. Controller & CAO | Sale | 5,189 | $154.74 | $802,946 | 34,941 | Nov 6, 2024 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sale | 1,775 | $156.92 | $278,533 | 9,734 | Oct 28, 2024 |
| Gregg Vicky B | — | L | 76 | $149.37 | $11,352 | 18,045 | Oct 21, 2024 |
| DELANEY MARK E | SVP & Chief Commercial Officer | L | 4 | $149.39 | $598 | 5,023 | Oct 21, 2024 |
| SAMAD SAM | Executive Vice President & CFO | L | 37 | $149.37 | $5,527 | 17,504 | Oct 21, 2024 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | 21 | $149.37 | $3,137 | 11,509 | Oct 21, 2024 |
| Plewman Patrick | SVP for Diagnostic Services | L | 60 | $149.37 | $8,962 | 16,258 | Oct 21, 2024 |
| GARDNER MARK A | SVP of Molecular Gen & Oncol | Tax Withholding | 120 | $155.70 | $18,684 | 4,673 | Sep 24, 2024 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Option Exercise | 32,551 | $95.80 | $3,118,386 | 71,029 | Aug 29, 2024 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sale | 1,990 | $153.26 | $304,987 | 11,459 | Aug 28, 2024 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Tax Withholding | 74 | $149.46 | $11,060 | 13,449 | Aug 14, 2024 |